Galmed Pharmaceuticals
GLMD
S$2.46
Share price
-4.02%
Change (1 day)
-51.74%
Change (1 year)
Categories
Revenue for Galmed Pharmaceuticals (GLMD)
Revenue in 2025 (TTM): N/A
In 2024 the company made a revenue of N/A a decrease over the revenue in the year 2023 that were of N/A. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Galmed Pharmaceuticals from 2013 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
2025 (TTM)  | N/A | |
| 2024 | N/A | |
| 2023 | N/A | |
| 2022 | N/A | |
| 2021 | N/A | |
| 2020 | N/A | |
| 2019 | N/A | -100% |
| 2018 | S$2.78 M | 91.86% |
| 2017 | S$1.45 M | 114.71% |
| 2016 | S$0.67 M | |
| 2015 | N/A | |
| 2014 | N/A | |
| 2013 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Catalent CTLT | S$5.68 B | N/A | 🇺🇸 USA |
 Endo International
ENDPQ | S$2.58 B | N/A | 🇮🇪 Ireland |
 Aerie Pharmaceuticals AERI | S$0.27 B | N/A | 🇺🇸 USA |
 Evoke Pharma
EVOK | S$14.91 M | N/A | 🇺🇸 USA |